Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.47 |
| ▸ | ARG2 | P78540 | 2/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.44 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622475 | 0.89 | S1PR1 (0.42) | ARG1ARG2TNNC1S1PR1S1PR4 | |
| SCHEMBL14818917 | 0.86 | ARG1 (0.49) | ARG1ARG2TNNC1S1PR1S1PR4 | |
| SCHEMBL14145263 | 0.84 | ALOX5 (0.47) | ARG1ARG2IGF1RALOX15SPHK2 | |
| SCHEMBL13932736 | 0.81 | S1PR1 (0.66) | TNNC1S1PR1S1PR4S1PR3SGPL1 | |
| SCHEMBL13953044 | 0.79 | ALOX5 (0.48) | PPARA | |
| SCHEMBL2632241 | 0.78 | S1PR1 (0.61) | TNNC1S1PR1S1PR4S1PR3SGPL1 | |
| SCHEMBL7616078 | 0.75 | S1PR2 (0.44) | S1PR1S1PR4S1PR3IGF1RALOX15 | |
| SCHEMBL14499316 | 0.74 | GRM2 (0.50) | ARG1ARG2S1PR1S1PR3GRM2 | |
| SCHEMBL13932769 | 0.73 | S1PR1 (0.62) | TNNC1S1PR1S1PR4S1PR3SGPL1 | |
| SCHEMBL13953244 | 0.71 | ARG1 (0.36) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | ARG1 2516/4885ARG2 251/4885TNNC1 2891/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | ARG1 2516/4885ARG2 251/4885TNNC1 2891/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | ARG1 2516/4885ARG2 251/4885TNNC1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.